Abstract:Renin-angiotensin system (RAS) plays a key role in the development and progression of chronic kidney disease (CKD). Recent studies have demonstrated activation of Wnt/β-catenin pathway by RAS in CKD. However, the underlying mechanisms of RAS and Wnt/β-catenin signaling interaction and their contribution to the pathogenesis of CKD have not been fully elucidated. Present study is designed to investigate the role of RAS/Wnt/β-catenin axis activation in tubulo-interstitial fibrosis and glomerulosclerosis by the cultured HK-2 and podocytes. HK-2 cells and podocytes are treated by angiotensin II (Ang II). Ang II up-regulates expression of various Wnt mRNA and active β-catenin protein in HK-2 cells and podocytes in the time- and dose-dependent manners. In addition, Ang II induces injury, oxidative stress and inflammation and impaired Nrf2 activation in HK-2 cells and podocytes. This was accompanied by up-regulations of RAS components as well as Wnt1, activated β-catenin and its target proteins. RAS/Wnt/β-catenin axis activation results in epithelial-to-mesenchymal transition in HK-2 cells and injuries podocytes. The effect of Ang II is inhibited by losartan and ICG-001, a Wnt/β-catenin inhibitor. We further found that treatment with natural products, ergone, alisol B 23-acetate and pachymic acid B inhibit extracellular matrix accumulation in HK-2 cells and attenuated podocyte injury, in part, by inhibiting Ang II induced RAS/Wnt/β-catenin axis activation. In summary, activation of RAS/Wnt/β-catenin axis results in podocytes and tubular epithelial cell, injury and up-regulations of oxidative, inflammatory and fibrotic pathways. These adverse effects are ameliorated by ergone, alisol B 23-acetate and pachymic acid B. Therefore, these natural products could be considered as novel Wnt/β-catenin signaling inhibitors and anti-fibrotic agents.

Update on Signaling Pathways of Podocyte Injury

Understanding the podocyte immune responses in proteinuric kidney diseases: from pathogenesis to therapy

Molecular mechanisms involved in podocyte EMT and concomitant diabetic kidney diseases: an update

Role of Podocyte Injury in Glomerulosclerosis.

Research Progress on Mechanism of Podocyte Depletion in Diabetic Nephropathy

[New Insight in Pathogenesis of Podocyte Disfunction in Minimal Change Disease].

Podocyte injury of diabetic nephropathy: Novel mechanism discovery and therapeutic prospects

Role of RAS/Wnt/β-catenin Axis Activation in the Pathogenesis of Podocyte Injury and Tubulo-Interstitial Nephropathy

Podocyte Autophagic Activity Plays a Protective Role in Renal Injury and Delays the Progression of Podocytopathies.

Podocyte senescence: from molecular mechanisms to therapeutics

The Updates of Podocyte Lipid Metabolism in Proteinuric Kidney Disease

The β isoform of GSK3 mediates podocyte autonomous injury in proteinuric glomerulopathy.

Damage-Associated Molecular Patterns and Pattern Recognition Receptors in the Podocyte

PPAR-γ Signaling in Podocyte Injury

The Physiopathologic Roles of Calcium Signaling in Podocytes

Podocyte‐related Proteins in Membranous Nephropathy Progression

Innate Immune Activity In Glomerular Podocytes

Crosstalk among podocytes, glomerular endothelial cells and mesangial cells in diabetic kidney disease: an updated review

Integrated single-cell RNA-seq analysis revealed podocyte injury through activation of the BMP7/AMPK/mTOR mediated autophagy pathway

Research Progress on the Pathological Mechanisms of Podocytes in Diabetic Nephropathy

Podocyte-targeted therapies — progress and future directions